Lewy body dementia

Lewy body dementia
Name	Lewy body dementia
Specialty	Neurology, Geriatrics, Psychiatry
Symptoms	Fluctuating cognition, visual hallucinations, parkinsonism, REM sleep behavior disorder
Complications	Falls, aspiration pneumonia, delirium
Onset	Usually older adults
Duration	Progressive
Causes	Alpha-synuclein aggregation
Risks	Age, Parkinson disease, REM sleep behavior disorder, family history
Diagnosis	Clinical criteria, neuroimaging, polysomnography
Differential	Alzheimer disease, Parkinson disease dementia, vascular dementia, psychiatric disorders
Treatment	Cholinesterase inhibitors, antipsychotic avoidance, physical therapy, occupational therapy

Lewy body dementia Lewy body dementia is a progressive neurodegenerative syndrome characterized by cognitive fluctuations, visual hallucinations, parkinsonism, and sleep disturbances that overlap clinically and pathologically with other synucleinopathies. It commonly affects older adults and presents diagnostic and management challenges because of its sensitivity to antipsychotic agents and heterogeneous presentation across neuropsychiatric and motor domains. Care typically requires multidisciplinary teams integrating neurology, geriatrics, psychiatry, rehabilitation, and palliative services.

Introduction

Lewy body dementia lies within the spectrum of alpha-synuclein disorders alongside Parkinson disease, multiple system atrophy, and dementia with Lewy bodies (pathology), producing cognitive, motor, and neuropsychiatric features. First described in neuropathology studies influenced by the work of Friederich Lewy and later clinical delineation by clinicians connected to institutions such as Mayo Clinic and University College London, the syndrome bridges research streams from centers like National Institute on Aging, Massachusetts General Hospital, and Johns Hopkins Hospital. Epidemiological studies from populations in United States, United Kingdom, Japan, and Australia have informed prevalence estimates and informed diagnostic consensus panels convened by organizations such as the Alzheimer's Association and the Dementia Forum.

Signs and symptoms

Core clinical features include fluctuating attention and alertness, well-formed visual hallucinations, parkinsonian motor signs, and rapid eye movement sleep behavior disorder. Patients often present to specialists in Neurology, Psychiatry, Geriatrics Medicine, or Ophthalmology with complaints documented in memory clinics at institutions like King's College Hospital or Cleveland Clinic. Visual hallucinations may involve familiar faces or scenes and lead families to seek input from community groups such as Alzheimer's Society or patient advocacy organizations like Lewy Body Dementia Association. Autonomic features—orthostatic hypotension, constipation, urinary dysfunction—prompt referrals involving tertiary centers including Mayo Clinic Scottsdale and Mount Sinai Hospital. Neuropsychiatric manifestations may include depression, anxiety, apathy, and paranoia, often managed collaboratively by teams in hospitals like Beth Israel Deaconess Medical Center.

Causes and pathophysiology

Pathologically, the syndrome is defined by cortical and brainstem neuronal inclusions composed predominantly of misfolded alpha-synuclein, discovered through laboratory research inspired by work at institutions such as Cold Spring Harbor Laboratory, Salk Institute, and Karolinska Institutet. Genetic influences include variants in genes studied at research centers such as Broad Institute and UCL Genetics Institute—for example in SNCA, GBA, and LRRK2—which modulate risk and phenotype. Environmental and comorbid contributors have been explored in cohort studies from Framingham Heart Study and populations in Rotterdam Study and Baltimore Longitudinal Study of Aging. Neurochemical changes include cholinergic deficits identified in tracer studies from PET Research Unit groups at University of Pittsburgh and Stanford University School of Medicine, while synaptic and network dysfunctions are investigated using methods developed at Massachusetts Institute of Technology and Max Planck Institute for Human Cognitive and Brain Sciences.

Diagnosis

Diagnosis is clinical, guided by consensus criteria from panels convened by organizations like the Alzheimer's Association and the World Health Organization; supportive testing includes structural MRI, functional imaging such as dopamine transporter single-photon emission computed tomography performed at centers like Imperial College Healthcare and Vanderbilt University Medical Center, and Polysomnography for REM sleep behavior disorder assessed in sleep centers at University of California, San Francisco and Brigham and Women's Hospital. Differential diagnosis requires exclusion of conditions seen in referrals to specialty clinics at Mount Sinai, Royal Melbourne Hospital, and Toronto Western Hospital—notably Alzheimer disease, vascular dementia, and primary psychiatric disorders treated at institutions like McLean Hospital. Neuropsychological assessment by teams affiliated with Neuropsychology Service, Beth Israel or University College London Hospitals helps characterize the attentional-executive and visuospatial profile.

Management and treatment

Management is multidisciplinary, integrating pharmacologic and nonpharmacologic strategies implemented in clinics at Johns Hopkins Hospital, Massachusetts General Hospital, and Guy's and St Thomas' NHS Foundation Trust. Cholinesterase inhibitors studied in randomized trials at centers like University of Oxford and Karolinska University Hospital can improve cognition and visual hallucinations; levodopa may partially address parkinsonism with caution about exacerbating psychosis, an approach taught in specialist programs at Stanford Medicine. Antipsychotic sensitivity—particularly to agents like haloperidol—requires avoidance of many typical antipsychotics and careful use of alternatives under guidance from groups such as Royal College of Psychiatrists and American Psychiatric Association. Nonpharmacologic interventions include occupational therapy, physical therapy, and tailored sleep management developed in rehabilitation services at Spaulding Rehabilitation Hospital and Royal National Hospital for Neurology and Neurosurgery. Caregiver support and advance care planning are provided by community resources such as Alzheimer's Society, Age UK, and National Institute for Health and Care Excellence guidance programs.

Prognosis and disease course

The disease course is progressive, with median survival after diagnosis estimated from cohorts at centers like Mayo Clinic and Addenbrooke's Hospital to be several years, though variability is high depending on comorbidities, age at onset, and complications such as pneumonia and falls managed in hospitals like Royal Infirmary of Edinburgh and Toronto General Hospital. Cognitive and motor decline tends to advance, often necessitating transitions to higher levels of care coordinated through health systems like National Health Service clinics and Veterans Health Administration facilities. Research networks including European DLB Consortium and Lewy Body Dementia Association Research Consortium continue to study disease modifiers, biomarkers, and therapeutic trials conducted at universities such as Harvard Medical School and University of California, Los Angeles.

Category:Neurodegenerative diseases